CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

yahoo_finance
Original article

Oppenheimer Adjusts PT on Corbus Pharmaceuticals to $52 From $54, Maintains Outperform Rating

Neutral
AI Analysis

Summary

Oppenheimer lowered its price target on Corbus Pharmaceuticals from $54 to $52 while maintaining an Outperform rating.

Importance:2/10
Sentiment:
0.00
price_targetanalyst_ratingequity_research
Related Companies

Read the original article

Published by yahoo_finance on June 17, 2026 12:31 PM

Read Original